Key result
Systemic ET(B) receptor blockade with A-192621 produced sustained hypertension in conscious mice that was reversed or prevented by the ET(A) antagonist atrasentan.
Why the study?
Does ET(A) and ET(B) receptor blockade alter basal blood pressure and ET(B) blockade-induced hypertension in conscious mice?
Population
Conscious, telemetry-instrumented mice (n=22)
Comparison
ET selective antagonist A-192621 and/or ET… vs Baseline values and alternative sequences of…
Design
Preclinical
Follow-up
8 days
Authors
Loading...
Preclinical ET(B) blockade data warrant caution in models; leaves open ET(A) targeting for human hypertension.
Does ET(A) and ET(B) receptor blockade alter basal blood pressure and ET(B) blockade-induced hypertension in conscious mice?
ET(A) and ET(B) receptors play a physiologically relevant role in basal blood pressure regulation, and ET(A) receptors maintain the hypertension produced by ET(B) blockade in mice.
Fryer et al. (2006) studied Blood pressure regulation (n=22). ET(B) selective antagonist A-192621 and ET(A) selective antagonist atrasentan vs. Baseline was evaluated on Mean arterial pressure (MAP). Systemic ET(B) receptor blockade with A-192621 produced sustained hypertension in conscious mice that was reversed or prevented by the ET(A) antagonist atrasentan.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: